Alcami Strengthens Drug Product Manufacturing Team with New Leadership Roles

Alcami Announces Key Leadership Changes in Drug Product Manufacturing



Alcami Corporation, a prominent name in contract development and manufacturing organizations (CDMOs), has made significant strides in its leadership structure within the Drug Product division. On July 10, 2025, the company unveiled strategic appointments designed to bolster operational excellence and enhance the delivery of transformative medicines on a global scale.

Leadership Appointments Overview



The recent changes within Alcami's Drug Product team include the following key appointments:

1. Scott Jedrey - Vice President, Oral Solid Dose Operations at the Wilmington, North Carolina facility. With a remarkable tenure of 35 years at Alcami, Scott has rich experience across Manufacturing and Quality Operations. His leadership skills have been pivotal in maintaining the Wilmington facility's reputation for high-quality oral solid dose manufacturing.

2. Jeff Tripp - Vice President, Sterile Operations at the Research Triangle Park (RTP) facility in Morrisville, NC. Jeff arrives with over 40 years of substantial experience in drug manufacturing, having held senior positions at major companies such as Genentech/Roche and Allergan/AbbVie. His capability in sterile fill-finish processes and lean manufacturing will be instrumental in fostering innovation at the RTP site.

3. Tyler Ewald - Vice President, Sterile Operations in Charleston, SC. Tyler, possessing over 15 years of experience, previously led the Wilmington site’s manufacturing and packaging operations. His commitment to servant leadership and his extensive experience with various dosage forms, including sterile and semi-solid products, will aid in advancing operations at the Charleston facility.

A Unified Vision for Growth



The driving force behind these appointments is Tori E. Arens, President of Drug Product. With a unified vision and the combined expertise of Scott, Jeff, and Tyler, Alcami is strategically positioned to scale its capabilities in drug product manufacturing effectively. These leadership roles are not just about filling positions; they underscore Alcami's dedication to delivering high-quality therapies rapidly and reliably, catering to the ever-evolving needs of patients worldwide.

About Alcami



Founded over 45 years ago and headquartered in North Carolina, Alcami has been at the forefront of pharmaceuticals and biologics, transitioning them seamlessly from development stages to market delivery. The company prides itself on offering fully integrated lab services, cGMP-compliant drug product manufacturing, and a comprehensive array of support services. Its private equity investors include GHO Capital, The Vistria Group, and Ampersand Capital Partners. To learn more about Alcami and its initiatives, visit their official website.

In conclusion, Alcami’s recent leadership appointments reinforce its commitment to excellence and innovation in drug product manufacturing, setting the stage for future growth and enhanced service delivery for pharmaceutical clients across the globe.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.